{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:00Z","timestamp":1792123620212,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jiac.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T01:15:57Z","timestamp":1495070157000},"page":"774-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient"],"prefix":"10.1016","volume":"23","author":[{"given":"Hiroaki","family":"Kanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyofumi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Seishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.04.007_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: a review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2017.04.007_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jiac.2017.04.007_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.04.007_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jiac.2017.04.007_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jiac.2017.04.007_bib6","series-title":"Common terminology criteria for adverse events (CTCAE) version 4.03","author":"U.S. Department of Health and Human Services","year":"2010"},{"key":"10.1016\/j.jiac.2017.04.007_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma","volume":"73","author":"Ivashko","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2017.04.007_bib8","first-page":"1","article-title":"Bilateral anterior uveitis associated with nivolumab therapy","volume":"6","author":"Karlin","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jiac.2017.04.007_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.39406","article-title":"Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment","volume":"68","author":"de Velasco","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jiac.2017.04.007_bib10","article-title":"Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient","author":"Arai","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jiac.2017.04.007_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jiac.2017.04.007_bib12","doi-asserted-by":"crossref","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"10.1016\/j.jiac.2017.04.007_bib13","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1167\/iovs.08-2846","article-title":"T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions","volume":"50","author":"Sugita","year":"2009","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jiac.2017.04.007_bib14","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1189\/jlb.3A1014-466RR","article-title":"Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs","volume":"97","author":"Lee","year":"2015","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jiac.2017.04.007_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17300922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17300922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:55Z","timestamp":1761159415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17300922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1341321X17300922"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.04.007","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}